產品詳情
簡單介紹：
Anti-Phospho-Paxillin(Ser178)抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-Phospho-Paxillin(Ser178)抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-Phospho-Paxillin(Ser178)
Cat. Number:
Anti-Phospho-Paxillin(Ser178)抗體KL-5550R
Quantity size:
0.1ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Paxillin is a 64 kDa cytoskeletal adapter protein involved in organisation and function of focal adhesions, which are critical to cell adhesion and migration. This in turn plays a role in a wide variety of processes including embryogenesis, organogenesis, wound repair, inflammation and cancer. Paxillin contains LD motifs,Anti-Phospho-Paxillin(Ser178)抗體LIM domains, SH3 and SH2 binding domains that serve as docking sites for cytoskeletal proteins, tyrosine kinases (e.g., FAK, Pyk 2, Src), serine/threonine kinases, GTPase activating proteins and other adaptor proteins (e.g., Actin, Vinculin, Crk).
Also known as:
PXN(phospho S178); Paxillin (phospho S178); Paxillin (phospho Ser178); p-Paxillin (Ser178); Paired box protein Pax 1; PAX 1; Anti-Phospho-Paxillin(Ser178)抗體PAX1; Paxillin alpha; PXN; PXN protein; FLJ16691; FLJ23042; FLJ16691; PAXI_HUMAN; Paxillin; PXN protein.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, .
●
Immunogen: KLH conjugated Anti-Phospho-Paxillin(Ser178)抗體Synthesised phosphopeptide derived from human Paxillin around the phosphorylation site of Ser178.
●
Predicted Molecular Weight: 65kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-Phospho-Paxillin(Ser178)抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-Phospho-Paxillin(Ser178)抗體
Optimal working dilutions must be determined by the end user.
